| THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Patent applications |
| Patent application number | Title | Published |
|---|
| 20110245210 | THALIDOMIDE ANALOGS - Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs. | 10-06-2011 |
| 20110008255 | BETA-AMYLOID PET IMAGING AGENTS - Novel derivatives of imidazopyridinylbenzeneamines and novel derivatives of benzothiazolylbenzeneamines are disclosed that offer improved behavior when used as imaging agents for positron emission tomography of beta-amyloids. Also disclosed is a palladium-catalyzed reaction scheme under microwave conditions for aryl thioethers in general that provides a high ratio of substitution relative to reduction and can be used for the imidazopyridinylbenzeneamine derivatives as well as other compounds of related structure. | 01-13-2011 |
| 20100239601 | METHOD OF IMMUNIZING HUMANS AGAINST SALMONELLA TYPHI USING A VI-REPA CONJUGATE VACCINE - This invention relates to conjugates of the Vi polysaccharide of | 09-23-2010 |
| 20100104507 | USE OF STERICALLY STABILIZED CATIONIC LIPOSOMES TO EFFICIENTLY DELIVER CPG OLIGONUCLEOTIDES IN VIVO - Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapuslating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric molecule comprising a targeting molecule selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector molecule selected from the group consisting of a | 04-29-2010 |
